{"operation":"document","citation":"PI-95-011","title":"Northwest Natural Gas Company — Pipeline Safety Interpretation","source_type":"guidance","agency":"Pipeline and Hazardous Materials Safety Administration","status":"guidance","official":true,"published_on":"1995-05-08","effective_on":null,"summary":"PI-95-011 response to Northwest Natural Gas Company concerning 199.3.","machine_formats":{"json":"https://regulus.evalyn.ai/document/phmsa-interpretation-pi-95-011.json","markdown":"https://regulus.evalyn.ai/document/phmsa-interpretation-pi-95-011.md"},"app_url":"https://regulus.evalyn.ai/document/phmsa-interpretation-pi-95-011","source_url":"https://www.phmsa.dot.gov/sites/phmsa.dot.gov/files/legacy/interpretations/Interpretation%20Files/Pipeline/1995/PI95011.pdf","body":"<<<PAGE 1>>>\n\nU.S. Department 400 Seventh Street, SW\nof Transportation Washington, DC 20590\nResearch and\nSpecial Programs\nAdministration\n(No Date)\nMs. Deborah Jacobsen, R.N.\nNorthwest Natural Gas Company\n220 N.W. Second Avenue\nPortland, Oregon 97209-3991\nDear Ms. Jacobsen:\nThis is in response to your correspondence dated May 8, 1995, pertaining to an employee who is using a\nprescription drug.\nThe Research and Special Programs Administration (RSPA) does not have any prohibitions in its drug\nrule against an employee’ s use of prescription drugs. Therefore, you may not test an individual for\nprescription drugs under the authority of the Research and Special Programs Administration.\nThank you for your inquiry. 366-6199.\nIf you need additional information please contact Catrina M. Pavlik on (202)\nSincerely,\nG. Tom Fortner\nDirector for Compliance\nand State Programs\nOffice of Pipeline Safety\n95-05-08.doc 199.3\n40.21","truncated":false,"body_characters":922}